Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0O1WX
|
||||
| Former ID |
DAP001465
|
||||
| Drug Name |
Ciprofloxacin XR
|
||||
| Synonyms |
ciprofloxacin; 85721-33-1; Ciprofloxacine; Ciprobay; Ciproxan; Ciprofloxacina; Ciprofloxacinum; Ciprofloxacino; Cipro IV; Ciproxina; Ciprinol; Bernoflox; Ciprodar; Cifloxin; Septicide; Bacquinor; Ciproquinol; Cipromycin; Ciprocinol; Cipro XR; Superocin; Ciprowin; Ciprolon; Ciproflox; Ciprecu; BAY q 3939; Spitacin; Quintor; Quinolid; Proflaxin; Probiox; Ipiflox; Zumaflox; Ciproxine; Ciprolin; Roxytal; Italnik; Fimoflox; Corsacin; Citopcin; Ciprogis; Rancif; Ciriax; Ciplus; Baflox; Loxan; Cilab; Cycin; Cixan; Unex; GW1843; Ciprofloxacin Hydrochloride; Ciprofloxacin intratympanic - Otonomy
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Bacterial infection [ICD-11: 1A00-1C4Z; ICD-10: A00-B99] | Approved | [1] | ||
| Gram-positive bacterial infection [ICD-11: 1B74-1G40] | Approved | [2] | |||
| Biliary cancer [ICD-11: 2E92.7; ICD-10: D13.4] | Phase 1 | [3] | |||
| Company |
Depomed Bayer
|
||||
| Structure |
 |
Download2D MOL |
|||
| Formula |
C17H18FN3O3
|
||||
| Canonical SMILES |
C1CC1N2C=C(C(=O)C3=CC(=C(C=C32)N4CCNCC4)F)C(=O)O
|
||||
| InChI |
1S/C17H18FN3O3/c18-13-7-11-14(8-15(13)20-5-3-19-4-6-20)21(10-1-2-10)9-12(16(11)22)17(23)24/h7-10,19H,1-6H2,(H,23,24)
|
||||
| InChIKey |
MYSWGUAQZAJSOK-UHFFFAOYSA-N
|
||||
| CAS Number |
CAS 85721-33-1
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
854234, 7849275, 8188389, 12012611, 14780446, 43120033, 50065329, 50125725, 57314943, 80847453, 81043820, 85174197, 92722913, 93305520, 99319459, 104327163, 115354412, 118836555, 125358728, 126603656, 126617874, 126653698, 126663877, 131328379, 131549783, 134338664, 135019641, 143449628, 143837408, 162251668, 163370746, 164788124, 165235301, 175267218, 175611737, 196107810, 223683480, 226414707, 249857489, 252427178
|
||||
| Target and Pathway | |||||
| Target(s) | Bacterial DNA gyrase (Bact gyrase) | Target Info | Modulator | [4], [5] | |
| Bacterial Penicillin binding protein (Bact PBP) | Target Info | Inhibitor | [2] | ||
| Candida Thymidylate synthase (Candi TMP1) | Target Info | Inhibitor | [6] | ||
| Staphylococcus Topoisomerase IV (Stap-coc parC) | Target Info | Modulator | [4], [5] | ||
| BioCyc | Pyrimidine deoxyribonucleotides biosynthesis from CTP | ||||
| Pyrimidine deoxyribonucleotides de novo biosynthesis | |||||
| Superpathway of pyrimidine deoxyribonucleotides de novo biosynthesis | |||||
| Superpathway of pyrimidine deoxyribonucleoside salvage | |||||
| DTMP de novo biosynthesis (mitochondrial) | |||||
| Pyrimidine deoxyribonucleosides salvage | |||||
| KEGG Pathway | Pyrimidine metabolism | ||||
| One carbon pool by folate | |||||
| Metabolic pathways | |||||
| Panther Pathway | De novo pyrimidine deoxyribonucleotide biosynthesis | ||||
| Formyltetrahydroformate biosynthesis | |||||
| Pathwhiz Pathway | Pyrimidine Metabolism | ||||
| Pathway Interaction Database | E2F transcription factor network | ||||
| Reactome | E2F mediated regulation of DNA replication | ||||
| Pyrimidine biosynthesis | |||||
| G1/S-Specific Transcription | |||||
| WikiPathways | Trans-sulfuration and one carbon metabolism | ||||
| Retinoblastoma (RB) in Cancer | |||||
| One Carbon Metabolism | |||||
| Integrated Pancreatic Cancer Pathway | |||||
| miR-targeted genes in muscle cell - TarBase | |||||
| miR-targeted genes in lymphocytes - TarBase | |||||
| miR-targeted genes in leukocytes - TarBase | |||||
| miR-targeted genes in epithelium - TarBase | |||||
| Metabolism of nucleotides | |||||
| Fluoropyrimidine Activity | |||||
| References | |||||
| REF 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | ||||
| REF 2 | Emerging drugs for bacterial urinary tract infections. Expert Opin Emerg Drugs. 2005 May;10(2):275-98. | ||||
| REF 3 | Low folate conditions may enhance the interaction of trifluorothymidine with antifolates in colon cancer cells. Cancer Chemother Pharmacol. 2006 Jan;57(2):171-9. | ||||
| REF 4 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. | ||||
| REF 5 | DOI: 10.1093/jac/48.4.479 | ||||
| REF 6 | Loss of folylpoly-gamma-glutamate synthetase activity is a dominant mechanism of resistance to polyglutamylation-dependent novel antifolates in multiple human leukemia sublines. Int J Cancer. 2003 Feb 20;103(5):587-99. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Wang and Dr. Li.